Atara Biotherapeutics
ATRA
111 hedge funds and large institutions have $535M invested in Atara Biotherapeutics in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 22 reducing their positions, and 25 closing their positions.
140% more call options, than puts
Call options by funds: $717K | Put options by funds: $299K
123% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.22% less ownership
Funds ownership: 4.52% → 4.29% (-0.22%)
5% less funds holding
Funds holding: 117 → 111 (-6)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
47% less capital invested
Capital invested by funds: $1.01B → $535M (-$472M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$14.8M |
| 2 |
AG
Artal Group
Luxembourg
|
+$9.52M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$8.19M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.68M |
| 5 |
Morgan Stanley
New York
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$18.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$12.2M |
| 3 |
BM
Bridger Management
New York
|
-$8.72M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.94M |
| 5 |
CFM
Coronation Fund Managers
Cape Town,
South Africa
|
-$3.26M |
ATRA Hedge Fund Activity: Q1 2020 in Review
111 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2020, worth a combined $535M — down 47% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ATRA and 22 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 49 added.
The largest buyer was Farallon Capital Management, adding an estimated $14.8M. The largest seller was Camber Capital Management, cutting an estimated $18.7M.
- 111 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2020, down from 117 in Q4 2019.
- Funds reported $535M of Atara Biotherapeutics stock for Q1 2020, down 47% quarter-over-quarter.
- 22 funds opened new Atara Biotherapeutics positions in Q1 2020 and 25 closed out, a net change of -3 holders.
- The largest Atara Biotherapeutics buyer in Q1 2020 was Farallon Capital Management, an estimated $14.8M added.
- The largest Atara Biotherapeutics seller in Q1 2020 was Camber Capital Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q1 2020.